02/01/23 4:30 PMNasdaq : MRTX conferencesMirati Therapeutics to Participate in Two Upcoming Healthcare ConferencesMirati Therapeutics, Inc., a targeted oncology company, will participate in two upcoming healthcare conferences. Wednesday, February 8 at 7:45 a.m. PT/ 10:45 a.m. ET at the Guggenheim Healthcare Talks: Oncology Day Conference. Laurie Stelzer, chief financial officer, and Alan Sandler, chief medical officer, will represent the company in a fireside chat at the...RHEA-AIneutral
01/19/23 5:00 PMNasdaq : MRTX clinical trialMirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133Mirati Therapeutics, Inc., announced today the U.S. Food and Drug Administration has cleared the Investigational New Drug application of MRTX1133, a potential first-in-class oral KRAS G12D selective inhibitor for clinical evaluation. This particular mutation has been difficult to target, and we are confident in our novel oral formulation strategy, which...RHEA-AIneutral
12/22/22 4:30 PMNasdaq : MRTX conferencesMirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceMirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41 st J.P. Morgan Annual Healthcare Conference, on January 9, 2023. David Meek , chief executive officer, will makeRHEA-AIneutral
12/21/22 5:00 PMNasdaq : MRTX clinical trialMirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal CancerU.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for adagrasib (KRAZATI TM) in combination with cetuximab in patients with KRAS G12C -mutated advanced colorectal cancer (CRC) whose cancer has progressed following prior treatment with chemotherapy and anRHEA-AIpositive
12/13/22 4:00 PMNasdaq : MRTX Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 11 new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2022RHEA-AIvery positive
12/13/22 5:00 AMNYSE, Nasdaq : QGEN, MRTX fda approvalQIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancerQIAGEN has announced the U.S. Food and Drug Administration approval of its therascreen ® KRAS RGQ PCR kit as a companion diagnostic test to Mirati Therapeutic’ s drug KRAZATI ® for non-small cell lung cancer. QIAGEN and Mirati Therapeutics, Inc., a targeted oncology company, announced their cooperation in May 2021.RHEA-AIvery positive
12/12/22 6:42 PMNasdaq : MRTX Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationMirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI ™ ( adagrasib), a targeted treatment option for adult patients with KRASRHEA-AIvery positive
12/05/22 6:05 PMNasdaq : MRTX Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRAS G12C mutation Findings will be presented on December 7 at the 2022 ESMO Immuno-Oncology Annual Congress, as anRHEA-AIneutral
12/02/22 8:00 AMNasdaq : MRTX clinical trialMirati Therapeutics Announces Update for the Phase 3 SAPPHIRE StudyMirati Therapeutics, Inc. (NASDAQ: MRTX), aRHEA-AIneutral
11/28/22 8:00 AMNasdaq : MRTX conferencesMirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IOMirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancerRHEA-AIneutral